Vyvgart (efgartigimod alfa-fcab), currently approved in the U.S. for treating certain adults with generalized myasthenia gravis (gMG), safely eased disease severity in adolescents with the disease, according to new data from a Phase 2/3 trial. Called ADAPT JR (NCT04833894), the study is still recruiting younger children,…
News
Facing the daily challenges of myasthenia gravis (MG) requires more than medication: It demands diligent self-management, including careful attention to stress and rest, and a cautious navigation of the digital world. Those are the main takeaways from the webinar, “Pushing Back at MG: From Getting Informed to…
People who recover from myasthenia gravis (MG) after long-term treatment have higher numbers of certain subsets of monocytes — a type of immune cell — and lower numbers of others, a small study in China found. “Consistent with previous studies, our study further validated that dysregulation of immune cells,…
Vyvgart (efgartigamod) rapidly eased symptoms of generalized myasthenia gravis (gMG) and prevented complications before, during, and after surgery in a 23-year-old woman, a case study reported. The woman required surgery to remove a mass in her abdominal cavity while also experiencing a gMG flare-up. Clinicians successfully removed the…
Rystiggo (rozanolixizumab-noli) can be safely self-administered by people with myasthenia gravis (MG), according to data from a Phase 3 clinical trial. Based on these findings, at-home administration of Rystiggo was authorized earlier in 2025 in Japan and Europe. The work was funded by UCB, the company that sells Rystiggo.
Anxiety related to COVID-19 is more prevalent among people with myasthenia gravis (MG) than among the general population, a study in Germany shows. For individuals with MG, the most pronounced cause of such anxiety was the fear patients experienced about the consequences of a COVID-19 infection on their health.
People with myasthenia gravis (MG) have higher levels of a protein called neurofilament light chain (NfL) in their blood, especially if their symptoms are severe or start later in life, a recent study found. This means that NfL could help doctors track how the disease develops and decide on…
Neurologists consider the degree of clinical efficacy and the onset of action as the most important factors when making treatment decisions for their patients with generalized myasthenia gravis (gMG), according to a study. Still, there is variability, with some physicians considering the mode of treatment administration a more important…
A live, virtual panel at 6 p.m. EST on Oct. 23 will explore how people with myasthenia gravis (MG) can make lifestyle changes to reduce flares, have a more supportive relationship with their healthcare team, and find reliable information about the neuromuscular disorder. The free webinar, “Pushing Back…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CNP-106, an experimental treatment that Cour Pharmaceuticals is developing to reprogram the immune system in generalized myasthenia gravis (gMG). “Receiving orphan drug designation for CNP-106 is an important development and regulatory milestone for our…
Recent Posts
- Telitacicept eases symptoms in treatment-resistant gMG: Study
- Aesthetics aside, breast reduction surgery has made my breathing easier
- My twin’s diet changes again after a lactose intolerance diagnosis
- The dangers of misinformation in a world that craves certainty
- Being silent about my MG symptoms is like wearing a mask